Sep. 5 at 11:52 PM
$SSKN Keep in mind that Accelmed’s average price per share, by my estimates, is
$9.52. They own 27% of the company. Although they may have wanted more shares at this level, a prudent board would probably restrict them from adding. It will be interesting to see who bought the shares. We may never know because if no single new investor added 5% (about 250,000 shares) it doesn’t need to be reported. Cash on hand now, improving reimbursement, and a good management team is what we need to get back to an admittedly low 90mil market cap.
